INO
Inovio Pharmaceuticals, Inc.
Price Chart
Latest Quote
$1.09
-0.01 (-0.91%)
Current Price
| Previous Close | $1.10 |
| Open | $1.11 |
| Day High | $1.12 |
| Day Low | $1.08 |
| Volume | 947,146 |
Stock Information
| Shares Outstanding | 82.27M |
| Total Debt | $8.70M |
| Cash Equivalents | $37.68M |
| Net Income | $-84.93M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $89.68M |
| EPS (TTM) | $-1.58 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $61.51M |
| Income | $-84.93M |
| Book/sh | $0.07 |
| Cash/sh | $0.46 |
| Employees | 112 |
Financial Ratios
| Quick Ratio | 0.99 |
| Current Ratio | 1.04 |
| Debt/Eq | 143.30 |
Returns & Margins
| ROA | -76.36% |
| ROE | -296.36% |
Ownership
| Insider Ownership | 0.42% |
| Institutional Ownership | 47.30% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -2.66 |
| P/B | 14.73 |
Analyst Data
| Recommendation | none |
| Target Price | $5.83 |
Technical Indicators
| SMA20 | $1.14 |
| SMA50 | $1.20 |
| SMA200 | $1.75 |
| RSI | 34.78 |
| ATR | 0.0579 |
| Shares Float | 81.88M |
| Short Float | 22.57% |
| Short Ratio | 4.30 |
| Volatility | 1.47 |
| Rel Volume | 0.65 |
Performance History
| Week | -1.80% |
| Month | -13.49% |
| Quarter | -29.22% |
| 6 Months | -51.56% |
| YTD | -35.50% |
| Year | -47.09% |
| 3 Years | -81.83% |
| 5 Years | -98.97% |
| 10 Years | -98.90% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-25 | $1.09 | 947,146 |
| 2026-06-24 | $1.10 | 1,564,300 |
| 2026-06-23 | $1.13 | 1,178,700 |
| 2026-06-22 | $1.11 | 1,090,800 |
| 2026-06-18 | $1.12 | 2,757,500 |
| 2026-06-17 | $1.11 | 1,109,200 |
| 2026-06-16 | $1.11 | 1,357,600 |
| 2026-06-15 | $1.10 | 910,300 |
| 2026-06-12 | $1.10 | 1,108,700 |
| 2026-06-11 | $1.10 | 1,419,000 |
| 2026-06-10 | $1.09 | 881,400 |
| 2026-06-09 | $1.10 | 1,158,500 |
| 2026-06-08 | $1.09 | 1,436,500 |
| 2026-06-05 | $1.07 | 3,318,700 |
| 2026-06-04 | $1.16 | 1,307,900 |
| 2026-06-03 | $1.14 | 1,769,300 |
| 2026-06-02 | $1.21 | 1,531,400 |
| 2026-06-01 | $1.28 | 1,749,500 |
| 2026-05-29 | $1.31 | 1,151,100 |
| 2026-05-28 | $1.30 | 1,383,500 |
| 2026-05-27 | $1.25 | 1,416,800 |
| 2026-05-26 | $1.26 | 2,133,200 |
About Inovio Pharmaceuticals, Inc.
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses SynCon, to help engineer precisely designed plasmid DNA plasmids, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company's lead product candidate is INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade squamous intraepithelial lesions; INO-3112 for the treatment of HPV-related Oropharyngeal squamous cell carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 2/3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. The company's partners and collaborators ApolloBio Corporation, AstraZeneca, Coherus Biosciences, Defense Advanced Research Projects Agency, HIV Vaccines Trial Network, Kaneka Eurogentec, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter BioLogics, the University of Pennsylvania, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.
đ° Latest News
Inovio Pharmaceuticals Shareholders Back Board as INO-3107 FDA Review Advances
MarketBeat âĸ 2026-05-25T18:02:45Z
INO Stock Edges Up After Hours As Partner Reports Success In Cervical Dysplasia Trial
Stocktwits âĸ 2026-05-21T21:37:32Z
Inovio Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary
Moby âĸ 2026-05-14T12:30:00Z
Inovio Pharmaceuticals Inc (INO) Q1 2026 Earnings Call Highlights: Progress and Challenges in ...
GuruFocus.com âĸ 2026-05-14T05:02:33ZFull Transcript: Inovio Pharmaceuticals Q1 2026 Earnings Call
Benzinga âĸ 2026-05-13T22:22:17Z
Moderna Stock Loses Steam. Hantavirus Trade Fizzles as Officials Dismiss Pandemic Risk.
Barrons.com âĸ 2026-05-11T19:18:00Z
ACAD Q1 Earnings & Revenues Miss Estimates Despite Y/Y Sales Growth
Zacks âĸ 2026-05-07T15:42:00Z
Madrigal Q1 Earnings Beat, MASH Drug Sales Drive Top Line, Stock Up
Zacks âĸ 2026-05-07T15:35:00Z
RXRX Q1 Loss Narrower Than Expected, Revenues Decline Y/Y
Zacks âĸ 2026-05-07T15:30:00Z
RARE Q1 Loss Wider Than Expected, Sales Down Y/Y on Seasonal Effect
Zacks âĸ 2026-05-06T16:00:00Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $65,343 | $217,756 | $832,010 | $10,262,268 |
| Operating Revenue | $65,343 | $217,756 | $832,010 | $10,262,268 |
| Expenses | ||||
| Interest Expense | $0 | $177,833 | $1,222,789 | $1,253,952 |
| Total Expenses | $86,887,447 | $112,616,678 | $134,258,667 | $277,835,788 |
| Other Income Expense | $-543,957 | $555,636 | $-8,601,196 | $-13,607,410 |
| Other Non Operating Income Expenses | $-2,641,813 | $-3,163,711 | $-4,711,596 | $-3,861,584 |
| Net Non Operating Interest Income Expense | $2,420,160 | $4,589,160 | $6,910,501 | $3,528,078 |
| Interest Expense Non Operating | $0 | $177,833 | $1,222,789 | $1,253,952 |
| Operating Expense | $86,887,447 | $112,616,678 | $134,258,667 | $277,835,788 |
| General And Administrative Expense | $32,680,573 | $36,996,338 | $47,582,104 | $90,185,285 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-84,945,901 | $-107,254,126 | $-135,117,352 | $-279,818,065 |
| Net Interest Income | $2,420,160 | $4,589,160 | $6,910,501 | $3,528,078 |
| Interest Income | $2,420,160 | $4,766,993 | $8,133,290 | $4,782,030 |
| Normalized Income | $-86,553,913 | $-112,139,916 | $-130,454,607 | $-271,971,893 |
| Net Income From Continuing And Discontinued Operation | $-84,945,901 | $-107,254,126 | $-135,117,352 | $-279,818,065 |
| Total Operating Income As Reported | $-86,822,104 | $-112,398,922 | $-143,940,028 | $-267,573,520 |
| Net Income Common Stockholders | $-84,945,901 | $-107,254,126 | $-135,117,352 | $-279,818,065 |
| Net Income | $-84,945,901 | $-107,254,126 | $-135,117,352 | $-279,818,065 |
| Net Income Including Noncontrolling Interests | $-84,945,901 | $-107,254,126 | $-135,117,352 | $-279,818,065 |
| Net Income Continuous Operations | $-84,945,901 | $-107,254,126 | $-135,117,352 | $-279,818,065 |
| Pretax Income | $-84,945,901 | $-107,254,126 | $-135,117,352 | $-277,652,852 |
| Earnings From Equity Interest | $489,844 | $-1,166,443 | $773,145 | $-1,899,654 |
| Interest Income Non Operating | $2,420,160 | $4,766,993 | $8,133,290 | $4,782,030 |
| Operating Income | $-86,822,104 | $-112,398,922 | $-133,426,657 | $-267,573,520 |
| Special Income Charges | - | $0 | $-10,513,371 | $0 |
| Earnings From Equity Interest Net Of Tax | - | - | $0 | $-2,165,213 |
| Per Share | ||||
| Diluted EPS | $-1.81 | $-3.95 | $-6.09 | $-14.04 |
| Basic EPS | $-1.81 | $-3.95 | $-6.09 | $-14.04 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-83,565,083 | $-108,832,041 | $-125,728,280 | $-263,056,702 |
| Total Unusual Items | $1,608,012 | $4,885,790 | $-4,662,745 | $-7,846,172 |
| Total Unusual Items Excluding Goodwill | $1,608,012 | $4,885,790 | $-4,662,745 | $-7,846,172 |
| Reconciled Depreciation | $2,988,830 | $3,130,042 | $3,503,538 | $5,496,026 |
| EBITDA (Bullshit earnings) | $-81,957,071 | $-103,946,251 | $-130,391,025 | $-270,902,874 |
| EBIT | $-84,945,901 | $-107,076,293 | $-133,894,563 | $-276,398,900 |
| Diluted Average Shares | $46,886,413 | $27,160,863 | $22,173,662 | $19,885,182 |
| Basic Average Shares | $46,886,413 | $27,160,863 | $22,173,662 | $19,885,182 |
| Diluted NI Availto Com Stockholders | $-84,945,901 | $-107,254,126 | $-135,117,352 | $-279,818,065 |
| Gain On Sale Of Security | $1,608,012 | $4,885,790 | $5,850,626 | $-7,846,172 |
| Research And Development | $54,206,874 | $75,620,340 | $86,676,563 | $187,650,503 |
| Selling General And Administration | $32,680,573 | $36,996,338 | $47,582,104 | $90,185,285 |
| Other Gand A | $32,680,573 | $36,996,338 | $47,582,104 | $90,185,285 |
| Impairment Of Capital Assets | - | $0 | $10,513,371 | $0 |
| Minority Interests | - | - | - | $0 |
| Tax Provision | - | - | - | - |
Fetched: 2026-06-22
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $24,096,276 | $68,503,795 | $117,349,129 | $209,719,524 |
| Total Assets | $74,310,035 | $113,197,206 | $170,951,423 | $348,533,302 |
| Total Non Current Assets | $13,186,689 | $15,367,156 | $17,838,323 | $33,290,622 |
| Other Non Current Assets | $2,012,475 | $1,979,654 | $605,315 | $684,044 |
| Current Assets | $61,123,346 | $97,830,050 | $153,113,100 | $315,242,680 |
| Prepaid Assets | $2,610,432 | $2,517,465 | $5,414,097 | $20,130,481 |
| Receivables | $450 | $1,199,056 | $2,405,228 | $11,738,216 |
| Accounts Receivable | $450 | $1,199,056 | $2,405,228 | $11,738,216 |
| Cash Cash Equivalents And Short Term Investments | $58,512,464 | $94,113,529 | $145,293,775 | $252,998,756 |
| Cash And Cash Equivalents | $44,273,319 | $65,813,297 | $14,310,862 | $46,329,359 |
| Goodwill And Other Intangible Assets | - | - | $0 | $12,643,232 |
| Other Current Assets | - | - | $20,432 | $375,227 |
| Restricted Cash | - | - | $0 | $30,000,000 |
| Other Intangible Assets | - | - | - | $2,129,861 |
| Debt | ||||
| Total Debt | $9,367,826 | $11,865,187 | $30,209,242 | $32,074,399 |
| Long Term Debt And Capital Lease Obligation | $6,545,204 | $9,367,827 | $11,032,066 | $29,270,426 |
| Current Debt And Capital Lease Obligation | $2,822,622 | $2,497,360 | $19,177,176 | $2,803,973 |
| Net Debt | - | - | $2,459,792 | - |
| Current Debt | - | - | $16,770,654 | - |
| Other Current Borrowings | - | - | $16,770,654 | - |
| Long Term Debt | - | - | - | $16,614,840 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $50,213,759 | $44,693,411 | $53,602,294 | $126,170,546 |
| Total Non Current Liabilities Net Minority Interest | $6,545,204 | $9,367,827 | $11,032,066 | $29,302,472 |
| Current Liabilities | $43,668,555 | $35,325,584 | $42,570,228 | $96,868,074 |
| Other Current Liabilities | $29,067,162 | $13,255,188 | $109,407 | $2,562,704 |
| Payables And Accrued Expenses | $4,410,453 | $9,565,856 | $13,446,541 | $78,926,476 |
| Payables | $2,619,148 | $6,442,666 | $4,648,345 | $21,082,926 |
| Accounts Payable | $2,619,148 | $6,442,666 | $4,648,345 | $21,082,926 |
| Non Current Deferred Liabilities | - | - | $0 | $32,046 |
| Non Current Deferred Taxes Liabilities | - | - | $0 | $32,046 |
| Current Deferred Liabilities | - | - | - | $0 |
| Other Non Current Liabilities | - | - | - | - |
| Equity | ||||
| Common Stock Equity | $24,096,276 | $68,503,795 | $117,349,129 | $222,362,756 |
| Total Equity Gross Minority Interest | $24,096,276 | $68,503,795 | $117,349,129 | $222,362,756 |
| Stockholders Equity | $24,096,276 | $68,503,795 | $117,349,129 | $222,362,756 |
| Gains Losses Not Affecting Retained Earnings | $-637,963 | $-675,667 | $-662,601 | $-698,741 |
| Other Equity Adjustments | $-637,963 | $-675,667 | $-662,601 | $-698,741 |
| Retained Earnings | $-1,815,165,163 | $-1,730,219,262 | $-1,622,965,136 | $-1,487,847,784 |
| Long Term Equity Investment | $2,103,688 | $1,613,844 | $2,780,287 | $2,007,142 |
| Other | ||||
| Preferred Shares Number | $26 | $26 | $26 | $26 |
| Ordinary Shares Number | $68,996,647 | $36,099,991 | $22,793,074 | $21,090,943 |
| Share Issued | $68,996,647 | $36,099,991 | $22,793,074 | $21,090,943 |
| Tangible Book Value | $24,096,276 | $68,503,795 | $117,349,129 | $209,719,524 |
| Invested Capital | $24,096,276 | $68,503,795 | $134,119,783 | $238,977,596 |
| Working Capital | $17,454,791 | $62,504,466 | $110,542,872 | $218,374,606 |
| Capital Lease Obligations | $9,367,826 | $11,865,187 | $13,438,588 | $15,459,559 |
| Total Capitalization | $24,096,276 | $68,503,795 | $117,349,129 | $238,977,596 |
| Additional Paid In Capital | $1,839,830,405 | $1,799,362,625 | $1,740,954,074 | $1,710,888,191 |
| Capital Stock | $68,997 | $36,099 | $22,792 | $21,090 |
| Common Stock | $68,997 | $36,099 | $22,792 | $21,090 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $6,545,204 | $9,367,827 | $11,032,066 | $12,655,586 |
| Current Capital Lease Obligation | $2,822,622 | $2,497,360 | $2,406,522 | $2,803,973 |
| Pensionand Other Post Retirement Benefit Plans Current | $7,368,318 | $10,007,180 | $9,837,104 | $12,574,921 |
| Current Accrued Expenses | $1,791,305 | $3,123,190 | $8,798,196 | $57,843,550 |
| Investments And Advances | $2,103,688 | $1,613,844 | $2,780,287 | $2,007,142 |
| Net PPE | $9,070,526 | $11,773,658 | $14,452,721 | $17,956,204 |
| Accumulated Depreciation | $-17,421,972 | $-16,462,447 | $-20,851,913 | $-21,563,403 |
| Gross PPE | $26,492,498 | $28,236,105 | $35,304,634 | $39,519,607 |
| Leases | $11,815,492 | $11,761,522 | $15,917,596 | $15,803,108 |
| Other Properties | $9,491,485 | $10,949,138 | $13,030,433 | $15,528,311 |
| Machinery Furniture Equipment | $5,185,521 | $5,525,445 | $6,356,605 | $8,188,188 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $14,239,145 | $28,300,232 | $130,982,913 | $206,669,397 |
| Duefrom Related Parties Current | - | $1,199,056 | $2,405,228 | $10,036,490 |
| Treasury Shares Number | - | - | $0 | - |
| Goodwill | - | - | $0 | $10,513,371 |
| Non Current Deferred Revenue | - | - | - | $0 |
| Current Deferred Revenue | - | - | - | $0 |
| Investmentsin Associatesat Cost | - | - | - | $2,007,142 |
| Investmentsin Subsidiariesat Cost | - | - | - | - |
Fetched: 2026-06-22
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-88,915,128 | $-104,564,385 | $-124,686,449 | $-217,184,574 |
| Operating Activities | ||||
| Operating Cash Flow | $-88,629,430 | $-104,076,553 | $-124,365,551 | $-216,215,421 |
| Cash Flow From Continuing Operating Activities | $-88,629,430 | $-104,076,553 | $-124,365,551 | $-216,215,421 |
| Operating Gains Losses | $-92,159 | $240,738 | $4,350,656 | $9,004,443 |
| Investing Activities | ||||
| Capital Expenditure | $-285,698 | $-487,832 | $-320,898 | $-969,153 |
| Investing Cash Flow | $14,039,357 | $104,071,039 | $87,355,875 | $109,585,856 |
| Cash Flow From Continuing Investing Activities | $14,039,357 | $104,071,039 | $87,355,875 | $109,585,856 |
| Capital Expenditure Reported | - | - | - | - |
| Financing Activities | ||||
| Issuance Of Capital Stock | $34,908,593 | $36,033,473 | $5,461,745 | $82,955,311 |
| Financing Cash Flow | $53,050,095 | $51,475,546 | $4,995,099 | $81,840,702 |
| Cash Flow From Continuing Financing Activities | $53,050,095 | $51,475,546 | $4,995,099 | $81,840,702 |
| Net Other Financing Charges | $-110,783 | $-420,795 | $-466,646 | $-1,397,631 |
| Net Common Stock Issuance | $34,908,593 | $36,033,473 | $5,461,745 | $82,955,311 |
| Common Stock Issuance | $34,908,593 | $36,033,473 | $5,461,745 | $82,955,311 |
| Other | ||||
| Repayment Of Debt | $0 | $-16,415,000 | $0 | - |
| Interest Paid Supplemental Data | $0 | $533,487 | $1,066,975 | $1,066,975 |
| End Cash Position | $44,273,319 | $65,813,297 | $14,310,862 | $46,329,359 |
| Beginning Cash Position | $65,813,297 | $14,310,862 | $46,329,359 | $71,143,778 |
| Effect Of Exchange Rate Changes | $0 | $32,403 | $-3,920 | $-25,556 |
| Changes In Cash | $-21,539,978 | $51,470,032 | $-32,014,577 | $-24,788,863 |
| Proceeds From Stock Option Exercised | $18,252,285 | $32,277,868 | $0 | $283,022 |
| Net Issuance Payments Of Debt | $0 | $-16,415,000 | $0 | $0 |
| Net Short Term Debt Issuance | $0 | $-16,415,000 | $0 | - |
| Short Term Debt Payments | $0 | $-16,415,000 | $0 | - |
| Net Investment Purchase And Sale | $14,325,055 | $104,499,552 | $81,457,510 | $112,555,007 |
| Sale Of Investment | $19,271,128 | $158,637,578 | $284,932,562 | $361,083,850 |
| Purchase Of Investment | $-4,946,073 | $-54,138,026 | $-203,475,052 | $-248,528,843 |
| Net PPE Purchase And Sale | $-285,698 | $-428,513 | $5,898,365 | $-969,153 |
| Sale Of PPE | $0 | $59,319 | $6,219,263 | $0 |
| Purchase Of PPE | $-285,698 | $-487,832 | $-320,898 | $-969,153 |
| Change In Working Capital | $-9,218,808 | $-2,664,952 | $-10,259,692 | $19,834,153 |
| Change In Other Working Capital | $-2,497,361 | $-1,573,401 | $-2,020,971 | $-2,689,945 |
| Change In Other Current Assets | $-32,821 | $38,900 | $78,729 | $741,750 |
| Change In Payables And Accrued Expense | $-7,794,265 | $-3,820,016 | $-54,217,752 | $32,874,388 |
| Change In Accrued Expense | $-1,371,180 | $-343,522 | $-8,228,691 | $267,807 |
| Change In Payable | $-6,423,085 | $-3,476,494 | $-45,989,061 | $32,606,581 |
| Change In Account Payable | $-6,423,085 | $-3,476,494 | $-45,989,061 | $32,606,581 |
| Change In Prepaid Assets | $1,105,639 | $2,689,565 | $39,020,611 | $-5,336,525 |
| Stock Based Compensation | $3,755,788 | $6,595,108 | $11,072,486 | $22,555,419 |
| Unrealized Gain Loss On Investment Securities | $-1,114,781 | $-2,077,182 | $-5,850,626 | $7,846,172 |
| Amortization Of Securities | $-2,399 | $-1,690,527 | $-4,686,144 | $-1,320,546 |
| Depreciation Amortization Depletion | $2,988,830 | $3,130,042 | $3,503,538 | $5,496,026 |
| Depreciation And Amortization | $2,988,830 | $3,130,042 | $3,503,538 | $5,496,026 |
| Depreciation | $2,988,830 | $3,130,042 | $3,358,121 | $4,999,532 |
| Earnings Losses From Equity Investments | $-489,844 | $1,166,443 | $-773,145 | $3,899,652 |
| Gain Loss On Investment Securities | $397,685 | $-903,239 | $4,805,804 | $4,029,961 |
| Gain Loss On Sale Of PPE | $0 | $-22,466 | $317,997 | $1,074,830 |
| Net Income From Continuing Operations | $-84,945,901 | $-107,254,126 | $-135,117,352 | $-279,818,065 |
| Change In Other Current Liabilities | - | $-109,407 | $-2,453,297 | $-2,049,343 |
| Change In Receivables | - | $1,206,172 | $9,332,988 | $-3,706,172 |
| Changes In Account Receivables | - | $1,206,172 | $9,332,988 | $-3,706,172 |
| Other Non Cash Items | - | $-355,654 | $155,814 | $186,977 |
| Asset Impairment Charge | - | $0 | $12,497,815 | $0 |
| Deferred Tax | - | $0 | $-32,046 | $0 |
| Deferred Income Tax | - | $0 | $-32,046 | $0 |
| Amortization Cash Flow | - | $0 | $145,417 | $496,494 |
| Amortization Of Intangibles | - | $0 | $145,417 | $496,494 |
| Net Business Purchase And Sale | - | - | $0 | $-1,999,998 |
| Purchase Of Business | - | - | $0 | $-1,999,998 |
| Issuance Of Debt | - | - | - | $0 |
| Income Tax Paid Supplemental Data | - | - | - | $1,066,975 |
| Net Long Term Debt Issuance | - | - | - | $0 |
| Long Term Debt Issuance | - | - | - | $0 |
| Sale Of Business | - | - | - | $0 |
| Gain Loss On Sale Of Business | - | - | - | $0 |
| Net Foreign Currency Exchange Gain Loss | - | - | - | - |
Fetched: 2026-06-22